Peer-reviewed Publications

Virus-based Cancer Immunotherapy Peer-reviewed Publications:

Journal of Medical Virology

Journal of Medical Virology

Kuryk and Mølleret al.
Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein‐2 cell entry receptor
Journal of Medical Virology onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25501

Journal of Medical Virology onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25501

Kuryket al.
Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
Int. J. Mol. Sci. 2019, 20, 621; doi:10.3390/ijms20030621

Int. J. Mol. Sci. 2019, 20, 621; doi:10.3390/ijms20030621

Kuryket al.
Optimization of Early Steps in Oncolytic Adenovirus. ONCOS-401 Production in T-175 and HYPERFlasks
ONCOIMMUNOLOGY https://doi.org/10.1080/2162402X.2018.1532763

ONCOIMMUNOLOGY https://doi.org/10.1080/2162402X.2018.1532763

Kuryket al.
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
J Med Virol. 2018;1–5. https://doi.org/10.1002/jmv.25229

J Med Virol. 2018;1–5. https://doi.org/10.1002/jmv.25229

Kuryket al.
Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model
Cancer Gene Therapy https://doi.org/10.1038/s41417-018-0038-x

Cancer Gene Therapy https://doi.org/10.1038/s41417-018-0038-x

Kuryket al.
Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401
PLoS ONE 12(8): e0182715. https://doi.org/10.1371/journal.pone.0182715

PLoS ONE 12(8): e0182715. https://doi.org/10.1371/journal.pone.0182715

Kuryket al.
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
International Journal of Cancer 2016 Jun 10. doi: 10.1002/ijc.30228

International Journal of Cancer 2016 Jun 10. doi: 10.1002/ijc.30228

Kuryket al.
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model
Journal for ImmunoTherapy of Cancer (Vol 4, Issue 17, 2016)

Journal for ImmunoTherapy of Cancer (Vol 4, Issue 17, 2016)

Rankiet al.
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers
Human Gene Therapy (Vol 26, Issue 8, 2015)

Human Gene Therapy (Vol 26, Issue 8, 2015)

Zamarinet al.
Replication-competent viruses as cancer immunotherapeutics: emerging clinical data
OncoImmunology (Vol 4, Issue 7, 2015)

OncoImmunology (Vol 4, Issue 7, 2015)

Vassilevet al.
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
OncoImmunology (Vol 3, Issue 10, 2014)

OncoImmunology (Vol 3, Issue 10, 2014)

Rankiet al.
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization